California Congresswoman Mary Bono Mack said she is perplexed that FDA inspectors continued to cite problems at the Novartis ($NVS) Lincoln, NE, plant without holding the drugmaker accountable. The incident highlights "the lack of predictability and consistency" in FDA interactions with manufacturers, and "emphasizes the need for more FDA oversight," she writes to FDA head Margaret Hamburg. Letter